United Pompe Foundation
  • Home
  • About
  • Clinical Trial Process
  • Donations
  • Resources
    • EP Magazine Article
    • Videos
    • Related Articles
    • Pompe Links
  • Contact Us
Select Page

Higher Lumizyme Dose May Help Prevent Pompe Progression in Infants, Case Report Suggests

by United Pompe | Jul 26, 2018 | News

Higher Lumizyme Dose May Help Prevent Pompe Progression in Infants, Case Report Suggests   JULY 18, 2018BY ALICE MELAOIN NEWS.     Treatment with Lumizyme(alglucosidase alfa) at double the approved dose may help prevent the rapid decline of respiratory...

Amicus Therapeutics Strengthens Biologics Business Strategy

by United Pompe | Jul 10, 2018 | News

Amicus Therapeutics Strengthens Biologics Business Strategy

Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease

by United Pompe | Mar 4, 2017 | News

PR NewsWire March 3, 2017 Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease Concord, MA– March 3, 2017– Valerion Therapeutics announced today that it has developed a fusion protein, VAL-1221, which combines its proprietary...

Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease

by United Pompe | Dec 8, 2016 | News

December 8, 2016 Amicus Therapeutics Announces Positive Preliminary Data from Phase 1/2 Study of Novel Treatment Paradigm for Pompe Disease ATB200/AT2221 Safety Data Show No Infusion-Associated Reactions Following 100+ Infusions Clinical Pharmacokinetic (PK) Profile...

Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease

by United Pompe | Nov 15, 2016 | News

PRESS RELEASE Sanofi Genzyme Begins Pivotal Phase 3 Trial of NeoGAA Investigational Second-Generation Therapy for Pompe Disease Cambridge, Mass. – November 4, 2016 – Sanofi Genzyme, the specialty care global business unit of Sanofi, announced today that the...
« Older Entries

Recent Posts

  • Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease
  • CLINICAL TRIALS/STUDIES
  • Higher Lumizyme Dose May Help Prevent Pompe Progression in Infants, Case Report Suggests
  • Amicus Therapeutics Strengthens Biologics Business Strategy
  • Valerion Therapeutics Demonstrates a New Mechanism for Treating Pompe Disease

Archives

  • September 2018
  • August 2018
  • July 2018
  • March 2017
  • December 2016
  • November 2016
  • July 2016
  • January 2016
  • October 2014

About

The United Pompe Foundation was formed to assist patients and/or their families with medical costs and other expenses that these patients and families face and may not be able to cover, or fully cover, through their insurance.

Contact

United Pompe Foundation
5100 N. Sixth Street #119
Fresno, CA 93710

Email: [email protected]
Phone: (559) 227-1898
Fax: (559) 227-1898

Copyright © 2018 United Pompe Foundation | All Rights Reserved | WUR